People · Operator
Named in public records as an officer, director or promoter · active 2018–2020 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vera Therapeutics, Inc. | — | Biotechnology | Series C | $70.7M | $2.6B | 2020 |
| Akero Therapeutics, Inc. | — | Pharma | Series C | $45.5M | $1.6B | 2018 |
Andrew Cheng at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Cheng on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 1 | 15 |
| Beth Seidenberg | 1 | 15 |
| Patrick Enright | 1 | 10 |
| Aaron Royston | 1 | 7 |
| SCOTT MORRISON | 1 | 6 |
| Aaron Kantoff | 1 | 6 |
| Kurt Von Emster | 1 | 6 |
| Maha Katabi | 1 | 6 |
| Mark Iwicki | 1 | 4 |
| Graham Walmsley | 1 | 2 |
| Marshall Fordyce | 1 | 1 |
| Jonathan Young | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.